El interés en corto de UTime da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de UTime. Los datos de interés en corto se actualizan cada dos semanas.

UTime (NASDAQ:WTO) Bolsa, Informe de interés en corto

UTime

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; and Do, as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

UTime Ltd

Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) reported quarterly sales of $94.200 million which missed the analyst consensus estimate of $95.450 million by 1.31 percent. This is a 20.96 percent decrease over sales of $119.184 million the same period last year.

Earnings

Earnings Misses

News

HNRG

Hallador Energy Q4 Sales $94.200M Miss $95.450M Estimate

Believes Proposed Transaction with Akoya Significantly Undervalues Quanterix
Encourages Shareholders to Vote Against Transaction to Protect Long-Term Value of their Investment
Kent Lake PR LLC ("Kent Lake") is a holder of 7.47% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>). Kent Lake has previously issued a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkentlake.s3.us-west-1.amazonaws.com%2FQTRX-AKYA_KLPRVoteNoDeck.pdf&amp;esheet=54224976&amp;newsitemid=20250317350313&amp;lan=en-US&amp;anchor=public+presentation&amp;index=1&amp;md5=3d2874e92fe780ca61d1f0c55f02e042">public presentation</a> detailing its opposition to the Company's proposed transaction (the "Transaction") with Akoya Biosciences ("Akoya") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>), and has also <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20250302423208%2Fen%2FKent-Lake-Nominates-Three-Highly-Qualified-Independent-Candidates-for-Quanterix-Board&amp;esheet=54224976&amp;newsitemid=20250317350313&amp;lan=en-US&amp;anchor=nominated&amp;index=2&amp;md5=ce02c5314a931458300c987ca9fdfcab">nominated</a> three highly qualified, independent candidates for election to the Company's Board of Directors (the "Board").
Kent Lake urges Quanterix management to address the following questions related to the Transaction on its earnings call today:
<ul>
<li>Disproportionate Value Distribution: Why does Quanterix continue to pursue a transaction that allocates over 82% of the combined company enterprise value to Akoya shareholders and less than 18% to Quanterix shareholders?</li>
<li>Akoya Going Concern: When evaluating Akoya's liquidity and going concern issues, as well as its potential impact on Quanterix shareholders' value, what key findings and assumptions did the Quanterix Board review and rely on to inform their M&amp;A evaluation and approve the terms of this merger, which awards Akoya shareholders a significant valuation premium on all metrics compared to Quanterix shareholders in spite of Akoya's going concern disclosures?</li>
<li>Conflicts of Interest: To what extent was Dr. Ivana Magovčević-Liebisch allowed to attend meetings, participate in discussions, and vote on matters related to the Akoya merger, despite her conflict of interest as a Board member at Akoya's key commercial diagnostic partner?</li>
<li>Material NIH Risk: Given that uncertainty around National Institutes of Health ("NIH") funding has led to a significant revaluation across the sector, and this uncertainty is material enough for peer companies to begin including new NIH-related risk factor disclosures in their FY 2024 10-K filings, how can Quanterix shareholders reasonably rely on the forward-looking statements, financial projections, fairness opinions, and purported merger benefits being presented that don't account for or contemplate this new material risk?</li>
<li>Akoya's Process: Given the S-4 discloses that Quanterix was bidding against itself by the end of the process, and that all other bidders had already walked away without making final offers due to concerning issues such as Akoya's high cash burn and debt, how is the Quanterix Board integrating this information into their fiduciary framework to continue to recommend the Merger?</li>
<li>The Board's Recommendation: Considering these outstanding issues and insufficient disclosures, what steps does the Quanterix Board plan to take to ensure they are fulfilling their fiduciary duties and are not required to withdraw their Merger recommendation?</li>
</ul>

Management

AKYA

QTRX

Kent Lake Urges Quanterix Management To Address Key Questions Regarding Its Proposed Transaction With Akoya Biosciences; Believes Proposed Transaction With Akoya Significantly Undervalues Quanterix; Encourages Shareholders To Vote Against Transaction To Protect Long-term Value Of Their Investment

Guidance

GETY

Getty Images Sees FY25 Revenue $918M-$955M Vs $954.667M Estimate; Sees Adj. EBITDA $272M-$290M

FGEN

FibroGen Q4 EPS From Continuing Operations $(0.08), Revenue From Continuing Operations $3.100M

Contracts

ICFI

ICF Secures Multiple Utility Demand-side Energy Management Contracts Valued At Over $35M To Deliver Its Residential And Commercial Demand-side Management Programs

Two insiders of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) sold large blocks of DJT shares last week, according to SEC filings. Here's a look at the details of the<a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock"> insider transactions.&nbsp;</a>
The Details: Trump Media CFO and treasurer Phillip Juhan sold approximately 21,000 shares in transactions totaling more than $431,000, according to a Form 4<a href="https://www.sec.gov/Archives/edgar/data/1808488/000147450625000055/xslF345X05/primary_doc.xml"> filing</a>. The sales were part of Juhan's previously <a href="https://www.sec.gov/Archives/edgar/data/1849635/000114036124045278/ef20038154_424b3.htm">disclosed</a> trading plan to sell 400,000 Trump Media &amp; Technology shares by December 2025.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/travel/25/03/44359238/severe-storm-system-brings-devastation-at-least-42-dead-power-outages-widespread-damage-reported">Severe Storm System Brings Devastation: At Least 42 Dead, Power Outages, Widespread Damage Reported&nbsp;</a>
Juhan still holds 220,577 shares of DJT, according to the filing, most of which are restricted stock units (RSUs) <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000234/xslF345X05/primary_doc.xml">awarded </a>to him on Nov. 5 that cannot be immediately sold.
One-quarter of Juhan&#8217;s restricted stock units became eligible for sale on Dec. 25, 2024, and the remaining shares will vest in quarterly installments through March 2027.
Eric Swider, TMTG director, sold 15,000 shares of DJT last week in transactions totaling nearly $300,000, according to his Form 4 <a href="https://www.sec.gov/Archives/edgar/data/1836937/000147450625000056/xslF345X05/primary_doc.xml">filing</a>. The filing also shows that on Feb. 25, 2025 18,043 Trump Media shares were transferred to Swider from Renatus LLC, a company he controls. 
Swider still owns 28,989 shares of Trump Media, some of which are restricted stock units that will vest according to the same schedule as Juhan's RSUs.&nbsp;
What Else: Trump Media &amp; Technology shares<a href="https://www.benzinga.com/general/social-media/25/03/44286296/trump-media-technology-stock-drops-50-since-inauguration-day"> have fallen</a> nearly 50% since President Donald Trump returned to the White House. inauguration. On Jan. 17, 2025, the last trading day before Trump's inauguration, the stock closed at $40.03.
The company, which is the parent of Trump&#8217;s Truth Social platform, will likely release its fourth-quarter results sometime in March, though an exact date has not been confirmed by the company.&nbsp;
DJT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Trump Media &amp; Technology Group shares were up 2.18% at $20.65 heading into Monday's closing bell.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44310724/doge-cuts-to-ftc-sow-confusion-in-case-against-amazon">DOGE Cuts To FTC Sow Confusion In Case Against Amazon</a>&nbsp;</li>
</ul>
Image: Shutterstock&nbsp;

Social Media

Insider Trades

Movers

General

Trump Media & Technology Insiders Dump Shares

Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 50 percent. This is a 33.33 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $247.30 million which beat the analyst consensus estimate of $246.31 million by 0.40 percent. This is a 9.45 percent increase over sales of $225.94 million the same period last year.

Earnings Beats

Getty Images Holdings Q4 2024 GAAP EPS $0.06 Beats $0.04 Estimate, Sales $247.30M Beat $246.31M Estimate

This Milestone Reflects the Company's Commitment to be a Strategic Partner for U.S. Government Customers
Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), a leading provider of team collaboration and productivity software, today announced that Atlassian Government Cloud has received Federal Risk and Authorization Management Program (FedRAMP) authorization at the Moderate level. FedRAMP is a U.S. government program that promotes the adoption of cloud technologies across the federal government by providing a standardized approach to validating security and risk controls for cloud-based products and services.

TEAM

Atlassian Achieves FedRAMP Moderate Authorization For Atlassian Government Cloud; Milestone Reflects The Company's Commitment To Be A Strategic Partner For U.S. Government Customers

Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) reported quarterly losses of $(2.43) per share which beat the analyst consensus estimate of $(2.69) by 9.67 percent. This is a 15.71 percent decrease over losses of $(2.10) per share from the same period last year.

RBOT

Vicarious Surgical Q4 2024 Adj. EPS $(2.43) Beats $(2.69) Estimate

SGMO

Sangamo Therapeutics Expects FY25 Operating Expenses On A Non-GAAP Basis Are To Be Roughly In Line With 2024

GOOG

GOOGL

"Alphabet And Wiz Held Deal Talks Last Year, Before Discussions Collapsed; Alphabet In Fresh Talks To Buy Cybersecurity Startup Wiz For $30B, Sources Say" - WSJ

Previously, the Company was provided a period of 180 calendar days, or until March 3, 2025, in which to regain compliance with the Rule.&nbsp; On March 7, 2025, the Company received notice from Nasdaq stating that the Company had not regained compliance with the Rule by the March 3 deadline and that its securities would be delisted from Nasdaq.
However, the Company's timely hearing request has automatically stayed the suspension of the Company's securities pending the Panel's decision. The stay, which allows for the continued trading of the Company's common stock on Nasdaq, will continue until the Panel issues a final determination regarding the Company's listing status. The Company intends

CNTM

ConnectM Requests Nasdaq Hearing For Continued Listing; Company's Timely Hearing Request Has Automatically Stayed The Suspension Of The Company's Securities Pending The Panel's Decision

Quanterix Expects 2025 Revenues $140M-$146M On Standalone Basis, Not Giving Effect To Akoya Acquisition

TTEC

TTEC Holdings Announces That TTEC Digital Will Expand Its Strategic Partnership With Verint By Providing Verint's End-to-end Cx Automation Platform As Part Of Ttec's Google Gcp Cloud Contact Center Portfolio

Quanterix Q4 2024 GAAP EPS $(0.30) Misses $(0.25) Estimate, Sales $35.200M Beat $34.437M Estimate

Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 22.73 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $21.34 million which met the analyst consensus estimate. This is a 19.42 percent decrease over sales of $26.49 million the same period last year.

Akoya Biosciences Q4 2024 GAAP EPS $(0.17) Misses $(0.16) Estimate, Sales $21.344M Beat $21.338M Estimate

Adagio Medical Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>, the "Company"))), a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia ("VT") solutions.
Recent Business Highlights:
<ul>
<li>The Company will participate in the scientific program of the 2025 European Heart Rhythm Association (the "Association") Annual Meeting to be held from March 30 through April 1 in Vienna, Austria.
<ul>
<li>At the Association's Ablation Innovation Summit, Dr. Tom De Potter, MD, PhD Associate Director, Cardiovascular Center at AZORG hospital in Aalst, Belgium will deliver a lecture on the use of the Company's proprietary ultra-low temperature cryoablation ("ULTC") technology for treatment of scar-related monomorphic ventricular tachycardia.</li>
<li>In addition, Professor Mark Gallagher, MD from St. George's University Hospital in London, UK, will present a first-in-human case series using ULTC for ablation of premature ventricular complexes ("PVC"). The ablations of idiopathic PVCs constitute over half of current VT ablation cases. ULTC uniquely addresses some of the procedural challenges associated with these ablations.</li>
</ul>
</li>
<li>The Company announced that the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia, NCT05675865) IDE Pivotal Study is over 40% enrolled. The trial, designed to support US premarket approval of the VT Cryoablation System with the vCLAS&#x2122; catheter is on track for completion of full patient enrollment in the second half of 2025. FULCRUM-VT is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory ventricular tachycardia in accordance with current treatment guidelines.
<ul>
<li>In alignment with its key initiatives, prioritizing the FULCRUM VT US pivotal trial and product design optimization, the Company announced that John Dahldorf, the Company's CFO, has decided to leave the Company, effective March 21, 2025. Mr. Dahldorf will be replaced by a transitional CFO.</li>
</ul>
</li>
</ul>

ADGM

Adagio Medical Announces Progress in Ventricular Tachycardia Solutions, FULCRUM-VT Trial Over 40% Enrolled; Participation In 2025 European Heart Rhythm Association Meeting; CFO John Dahldorf To Leave March 2025, Transitional CFO John Dahldorf Appointed

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 67.65 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $7.551 which missed the analyst consensus estimate of $13.617 million by 100.00 percent. This is a 100.00 percent decrease over sales of $2.042 million the same period last year.

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

BBIO

BridgeBio Names Thomas Trimarchi As President, CFO

HITI

High Tide Q1 2025 GAAP EPS C$(0.03), Sales C$142.461M

Press Releases

UTime Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

UTime Limited to Participate in International Medical Fairs and Medical Conferences

About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines

Remarkable Announcement on Significant Fluctuation of the UTime's Share Price

Markets

UTime Limited Announces 1-For-25 Reverse Share Split

UTime Limited Announces Pricing of $5 Million Registered Direct Offering

UTime Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Comments

UTime

Interés en corto

UTime (NASDAQ:WTO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL